Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01036763
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 173, Heilbronn, Germany
🇩🇪Boehringer Ingelheim Investigational Site 133, Germering, Germany
🇩🇪Boehringer Ingelheim Investigational Site 161, Hamburg, Germany
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 99
- Registration Number
- NCT01024920
- Locations
- 🇵🇱
Onco.Cent. - Instit. of Maria Sklodowskiej-Curie, Warszawa, Poland
🇭🇺University of Pecs Medical School, Dept. of Oncotherapy, Pecs, Hungary
🇵🇱Ziemia Lubelska Oncological Center, Lublin, Lublin, Poland
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
- Conditions
- Neoplasms
- Interventions
- Drug: BI 6727, IV infusion
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT01023958
- Locations
- 🇺🇸
1230.2.5 Boehringer Ingelheim Investigational Site, Beverly Hills, California, United States
🇺🇸1230.2.17 Boehringer Ingelheim Investigational Site, Joliet, Illinois, United States
🇺🇸1230.2.24 Boehringer Ingelheim Investigational Site, Metairie, Louisiana, United States
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT01022853
- Locations
- 🇮🇹
1230.7.39002 Boehringer Ingelheim Investigational Site, Ancona, Italy
🇮🇹1230.7.39001 Boehringer Ingelheim Investigational Site, Milano, Italy
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 470
- Registration Number
- NCT01019694
- Locations
- 🇺🇸
1012.62.117 Boehringer Ingelheim Investigational Site, Livonia, Michigan, United States
🇺🇸1012.62.126 Boehringer Ingelheim Investigational Site, Fort Collins, Colorado, United States
🇺🇸1012.62.123 Boehringer Ingelheim Investigational Site, Waterbury, Connecticut, United States
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
- Conditions
- Ovarian NeoplasmsPeritoneal Neoplasms
- Interventions
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1366
- Registration Number
- NCT01015118
- Locations
- 🇺🇸
1199.15.10019 Boehringer Ingelheim Investigational Site, Bismarck, North Dakota, United States
🇺🇸1199.15.10024 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States
🇺🇸1199.15.10107 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 198
- Registration Number
- NCT01013753
- Locations
- 🇦🇹
1222.27.43004 Boehringer Ingelheim Investigational Site, Schlüsslberg, Austria
🇵🇱1222.27.48001 Boehringer Ingelheim Investigational Site, Lodz, Poland
🇵🇱1222.27.48004 Boehringer Ingelheim Investigational Site, Proszowice, Poland
Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 491
- Registration Number
- NCT01012037
- Locations
- 🇨🇦
1218.62.11007 Boehringer Ingelheim Investigational Site, Burnaby, British Columbia, Canada
🇧🇪1218.62.32009 Boehringer Ingelheim Investigational Site, Kumtich, Belgium
🇳🇱1218.62.31001 Boehringer Ingelheim Investigational Site, Oude Pekela, Netherlands
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: BI 10773 placeboDrug: BI 10773 low doseDrug: BI 10773 high dose
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 494
- Registration Number
- NCT01011868
- Locations
- 🇺🇸
1245.33.01060 Boehringer Ingelheim Investigational Site, Fresno, California, United States
🇺🇸1245.33.01008 Boehringer Ingelheim Investigational Site, Los Gatos, California, United States
🇺🇸1245.33.01019 Boehringer Ingelheim Investigational Site, National City, California, United States
Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season
- Conditions
- Rhinitis, Allergic, SeasonalAsthma
- Interventions
- Drug: BI 67100 ED 25 mgDrug: BI 671800 ED 100 mgDrug: BI 671800 ED placeboDrug: 671800 ED placeboDrug: Fluticasonepropionate nasal spray 200 mcg
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 146
- Registration Number
- NCT01007721
- Locations
- 🇩🇪
1268.41.49001 Boehringer Ingelheim Investigational Site, Hannover, Germany